Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects-MedSci.cn

Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects

Liu, XX; Xue, L; Zhang, H; Xu, QQ; Zhang, SC; Ma, S; Ding, XL; Liu, LS; Dong, J; Qian, LF; Xia, W; Jiang, K; Huang, CR; Miao, LY

Huang, CR; Miao, LY (corresponding author), Soochow Univ, Dept Clin Pharmacol, Affiliated Hosp 1, 899 Pinghai St, Suzhou 215006, Peoples R China.; Miao, LY (corresponding author), Soochow Univ, Dept Pharmaceut, Coll Pharmaceut Sci, Suzhou, Peoples R China.

Abstract

Background and Objective Bentysrepinine (Y101), a derivative of repensine (a compound isolated from Dichondra repens Forst), is a novel phenylalanine ......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects

科室

工具

服务